



Promotions

Lisa Pavento Named Partner

March 1, 2017

Meunier Carlin & Curfman LLC is pleased to announce the election of Lisa Pavento to its partnership effective March 1, 2017.

Lisa's practice uniquely spans all major areas of intellectual property—prosecution, litigation and licensing in relation to each of patent, trademark, and copyright properties. Lisa began her career counselling clients regarding patents in the biotechnology space, where her background in immunology has enabled her to provide guidance in subject matters such as therapeutics, diagnostics, genomics, biopharmaceuticals, and drug delivery. Since then, Lisa's practice has expanded to include trademark, copyright, and licensing. Lisa regularly counsels clients regarding cost-effective trademark strategies, and the importance of mark clearance and selection prior to using a mark and/or filing of a trademark application. Lisa assists her clients with prosecuting trademark applications in the United States and throughout the world, and she manages trademark cancellation and opposition proceedings in both

domestic and international tribunals. Lisa also advises clients regarding copyright registration and litigation. She currently represents a client in a widely-observed copyright case involving issues of electronic reserves and fair use in the non-profit education context.

Lisa graduated *magna cum laude* with a B.S. in Microbiology from the University of Georgia after pursuing a pre-medical program. She spent three years working on a Ph.D. in Immunology from Emory University, with a specific focus on mechanisms of signal transduction by glycosyl-phosphatidylinositol anchored receptors. She then went to receive her J.D., *cum laude*, from the University of Georgia. Lisa is currently a Copyright Committee Member with the International Trademark Association (INTA).

“Lisa’s election to our partnership is well-deserved,” says managing partner, John Harbin. “She has built formidable trademark and copyright practices which are bolstered by her background in biotech patents.”